Earnings summaries and quarterly performance for Xenon Pharmaceuticals.
Executive leadership at Xenon Pharmaceuticals.
Board of directors at Xenon Pharmaceuticals.
Research analysts who have asked questions during Xenon Pharmaceuticals earnings calls.
Joseph Thome
TD Cowen
4 questions for XENE
Also covers: ALKS, AMLX, ARDX +12 more
Brian Abrahams
RBC Capital Markets
3 questions for XENE
Also covers: ACAD, ATAI, BCRX +17 more
Brian Skorney
Robert W. Baird & Co.
3 questions for XENE
Also covers: ABUS, CRNX, MIRM +6 more
Jason Gerberry
Bank of America Merrill Lynch
3 questions for XENE
Also covers: ALKS, AMPH, ARWR +21 more
Andrew Tsai
Jefferies
2 questions for XENE
Also covers: ARQT, ATAI, ATHA +13 more
BR
Basma Radwan Ibrahim
Leerink Partners
2 questions for XENE
Also covers: ACAD, AMLX, BLTE +2 more
PC
Paul Choi
Goldman Sachs
2 questions for XENE
Also covers: AMRN, ARVN, ASND +12 more
Paul Matteis
Stifel
2 questions for XENE
Also covers: ABOS, ACAD, ALKS +11 more
SS
Sarah Schram
William Blair
2 questions for XENE
Also covers: ALEC
Tessa Romero
JPMorgan Chase & Co.
2 questions for XENE
Also covers: ACAD, AGIO, CYTK +5 more
Caroline Kimberly Pocher
JPMorgan Chase & Co.
1 question for XENE
Also covers: MCRB
Cory Kasimov
Evercore ISI
1 question for XENE
Also covers: BBIO, BMRN, BNTX +5 more
DB
Danielle Brill
Truist Securities
1 question for XENE
Also covers: ACAD, ARGX, BBIO +5 more
DR
Dina Ramadane
Bank of America
1 question for XENE
Also covers: BLUE, TVTX
DT
Douglas Tsao
H.C. Wainwright & Co.
1 question for XENE
Also covers: ALKS, APLS, ARGX +19 more
DS
Dylan Shindler
Wedbush Securities
1 question for XENE
Emily Chudy
Stifel Financial Corp.
1 question for XENE
KC
Kyuwon Choi
Goldman Sachs
1 question for XENE
Also covers: AMRN, ASND, BHVN +9 more
Linda Tsai
Jefferies
1 question for XENE
Also covers: ADC, AKR, AMH +31 more
MG
Marc Goodman
Leerink Partners
1 question for XENE
Also covers: ACAD, ALDX, ALKS +14 more
MM
Matt Marcus
Jefferies Financial Group Inc.
1 question for XENE
MM
Myles Minter
William Blair & Company
1 question for XENE
Also covers: ALEC, ARCT, ARGX +11 more
Nevin
RBC Capital Markets
1 question for XENE
Recent press releases and 8-K filings for XENE.
Xenon Pharmaceuticals Provides Update on Azetukalner (AZK) and Pipeline at AES 2025
XENE
Product Launch
New Projects/Investments
Guidance Update
- Xenon Pharmaceuticals (XENE) presented data on its lead product, Azetukalner (AZK), a KV7 channel opener, at the American Epilepsy Society (AES) 2025 meeting, emphasizing its long-term efficacy and safety data from clinical studies in epilepsy patients.
- The 48-month XTOL Open Label Extension (OLE) data for AZK demonstrated a 91% median percent change reduction in focal onset seizure frequency from baseline for patients treated for at least 48 months, with a 100% reduction for those on one or two anti-seizure medications at baseline.
- Xenon is actively preparing for the potential commercialization of AZK for focal seizures, with market research suggesting its differentiated clinical profile (e.g., no titration, limited drug-drug interactions, fast onset of action) could drive broad adoption by epileptologists and general neurologists.
- The company expects its first AZK Phase 3 top-line data readout from the XTOL-2 study in early 2026.
- Beyond AZK, Xenon is advancing early-stage ion channel programs, including two molecules in Phase 1 for pain (XEN1120 and XEN1701) and a preclinical NAV1.1 program for Dravet syndrome.
Dec 10, 2025, 3:00 PM
Xenon Highlights Azetukalner (AZK) Data at AES 2025 and Commercial Preparations
XENE
Product Launch
New Projects/Investments
Guidance Update
- Xenon presented updated data for its lead drug, Azetukalner (AZK), at the American Epilepsy Society (AES) 2025 meeting, showcasing durable and sustained efficacy from its open-label extension study with over 800 patient years of exposure.
- The XTOL-2 Phase 3 study for focal onset seizures is fully enrolled, with top-line data anticipated in early 2026.
- In the open-label extension, AZK demonstrated a 91% median percent reduction in focal onset seizure frequency at 48 months, achieving 100% reduction for patients on one or two anti-seizure medications at baseline.
- Xenon is actively preparing for the potential commercial launch of AZK in focal seizures, noting its highly favorable profile among clinicians due to its novel mechanism, rapid onset, and ease of use (no titration, limited drug-drug interactions).
Dec 10, 2025, 3:00 PM
Xenon Pharmaceuticals Updates on Azetukalner Program and Commercial Readiness
XENE
New Projects/Investments
Product Launch
- Xenon Pharmaceuticals presented positive data for azetukalner (AZK) at the American Epilepsy Society (AES) 2025 meeting, including 48-month Open Label Extension (OLE) data showing a 91% median percent reduction in focal onset seizure frequency, and 100% for patients on one or two anti-seizure medications at baseline.
- The company anticipates its first Phase 3 top-line data readout for the X-TOLE2 study in early 2026, which, combined with existing data, will form the basis for a New Drug Application (NDA) in the U.S. for focal onset seizures.
- Commercialization preparations are underway, with market research indicating strong potential for AZK among both epileptologists and general neurologists due to its novel mechanism of action, ease of use (no titration), and limited drug-drug interactions.
- Xenon is expanding its commercial and medical affairs teams, with proactive outreach to payers planned for 2026 to support a successful launch.
Dec 10, 2025, 3:00 PM
Xenon Pharmaceuticals Provides Update on Azetukalner Phase 3 Development and Commercialization Efforts
XENE
Product Launch
New Projects/Investments
- Xenon Pharmaceuticals reported a strong financial position with $555.3 million in cash, cash equivalents, and marketable securities as of September 30, 2025, providing an anticipated cash runway into 2027.
- The company's lead molecule, azetukalner, is in Phase 3 development for epilepsy and depression. Long-term data from the X-TOLE Open-Label Extension showed a 90.9% median percent reduction in monthly focal onset seizure (FOS) frequency at 48 months. Additionally, 38% of patients treated with azetukalner for at least 48 months achieved seizure freedom for a period of one year or longer.
- Azetukalner has a well-documented safety profile with over 775 patient-years of safety data as of October 6, 2025, with long-term safety and tolerability comparable to the double-blind period. Topline Phase 3 X-TOLE2 data for azetukalner in FOS are anticipated in early 2026, and the company is investing in commercial and medical teams, with market access discussions with payors planned for 2026.
Dec 10, 2025, 3:00 PM
Xenon Provides Update on Azetukalner Clinical Programs and 2026 Outlook
XENE
Guidance Update
New Projects/Investments
Product Launch
- Xenon's lead molecule, azetukalner, a potassium channel modulator, is in development for epilepsy and neuropsychiatry.
- The Phase III X-TOLE2 study for focal onset seizures is fully enrolled with 380 subjects and is expected to read out in early 2026. Xenon anticipates filing an NDA in 2026 and potential approval in 2027.
- For neuropsychiatry, azetukalner has three Phase III clinical trials ongoing: two in Major Depressive Disorder (X-NOVA2, X-NOVA3) and one in bipolar depression (X-CEED). Data for the first MDD study is anticipated in approximately two to two and a half years from Q1 2025.
- Xenon also advanced two pain molecules into Phase I human clinical trials in 2025, including XEN1701 targeting Nav1.7.
Nov 19, 2025, 11:30 AM
Xenon Details Upcoming Milestones for Azetukalner and Pain Programs
XENE
Guidance Update
New Projects/Investments
- Xenon's lead molecule, azetukalner, is in Phase III development for epilepsy, with the first Phase III readout (XTOL II study) anticipated in early 2026 and an NDA filing expected in 2026. The company is conducting three Phase III epilepsy trials: XTOL II and XTOL III for focal onset seizures, and XACT for primary generalized tonic-clonic seizures.
- Azetukalner is also being developed for neuropsychiatry, with three Phase III clinical trials underway: two for Major Depressive Disorder (XNOVA II and XNOVA III) and one for Bipolar Depression (XCEED). The MDD studies are projected to take 2 to 2.5 years to complete, and the bipolar depression study is expected to take longer.
- The company's pain portfolio includes two molecules, XEN-1701 (targeting Nav1.7) and a Kv7 target, both of which entered Phase I human clinical trials in 2025. Phase I studies are expected to conclude in 2026, with Phase II proof-of-concept data in patients anticipated in 2027.
Nov 19, 2025, 11:30 AM
Xenon Pharmaceuticals Provides Clinical Program Updates and 2026 Outlook
XENE
Guidance Update
New Projects/Investments
- Xenon Pharmaceuticals' lead molecule, azetukalner, is in a Phase III XTOL II study for focal onset seizures, which is fully enrolled with 380 subjects and is expected to have data readout in early 2026.
- The company is also conducting three Phase III clinical trials for azetukalner in neuropsychiatry: two for major depressive disorder (XNOVA II and XNOVA III) and one for bipolar depression (XCEED). The MDD studies are expected to take 2 to 2.5 years to complete.
- Xenon plans to file an NDA in 2026 for epilepsy following the XTOL II readout, with EMA submission likely requiring both XTOL II and XTOL III data.
- The pain portfolio has two molecules, XEN-1701 (Nav1.7 target) and a Kv7 target drug, that have moved into Phase I human clinical trials this year, with plans to advance to Phase II proof-of-concept studies next year.
- Xenon expects to issue a press release at the beginning of 2026 to provide guidance and outline upcoming milestones.
Nov 19, 2025, 11:30 AM
Xenon Pharmaceuticals Provides Update on Clinical Programs and Financial Outlook
XENE
Guidance Update
New Projects/Investments
Product Launch
- Xenon Pharmaceuticals expects Phase 3 EXTOL-two data for Azetukalner in epilepsy in early 2026, with an NDA filing planned for next year. The Phase 3 population is similar to the Phase 2b study, which showed best-in-class efficacy.
- Azetukalner is also in two ongoing Phase 3 clinical trials for major depressive disorder and a recently initiated Phase 3 trial for bipolar depression, with MDD data estimated to be available in two to two and a half years.
- The company's early-stage pain portfolio includes two Phase 1 assets, XCN1701 (NaV1.7) and XCN1120 (Kv7), which are targeted to enter Phase 2 proof of concept studies in 2026.
- Xenon aims to move a molecule targeting NaV1.1 for Dravet syndrome into a human clinical trial next year.
- Xenon reported over $500 million in cash at the end of the last quarter, providing a cash runway into 2027.
Nov 13, 2025, 8:20 PM
Xenon Pharmaceuticals Provides Clinical Program Updates and Financial Outlook
XENE
Guidance Update
New Projects/Investments
Product Launch
- Xenon Pharmaceuticals' lead program, Azetukalner, has its Phase 3 EXTOL-two trial for epilepsy fully enrolled, with data expected in early 2026. The company plans to file a New Drug Application (NDA) next year following the phase 3 data.
- In psychiatry, Azetukalner is undergoing two Phase 3 clinical trials for Major Depressive Disorder (MDD) and a recently initiated Phase 3 trial for bipolar depression. The MDD Phase 3 data is estimated to take two to two and a half years to run.
- The company's early-stage pain portfolio includes two Phase 1 assets, XCN1701 (NaV1.7) and XCN1120 (Kv7), which are anticipated to enter Phase 2 proof-of-concept studies in 2026.
- Xenon Pharmaceuticals reported over $500 million in cash at the end of the last quarter, providing a cash runway into 2027.
Nov 13, 2025, 8:20 PM
Xenon Pharmaceuticals Provides Update on Clinical Pipeline and Financial Outlook
XENE
New Projects/Investments
Guidance Update
- Xenon Pharmaceuticals anticipates Phase III data for azetukalner in epilepsy (X-TOLE2) in early 2026, with an NDA filing expected in 2026.
- The company is progressing azetukalner in psychiatry with two ongoing Phase III studies for major depressive disorder and a recently initiated Phase III trial for bipolar depression.
- Two early-stage pain assets, XEN 1701 (NaV1.7) and XEN 1120 (Kv7), are in Phase I studies and are expected to enter Phase II proof-of-concept studies in 2026.
- Xenon reported over $500 million in cash at the end of the last quarter, providing a cash runway into 2027.
Nov 13, 2025, 8:20 PM
Quarterly earnings call transcripts for Xenon Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more